NumFin

LanZhou Foci Pharmaceutical Co.,Ltd.

Sümbol: 002644.SZ

SHZ

7.78

CNY

Turuhind täna

  • 68.3675

    P/E suhe

  • -2.3694

    PEG suhe

  • 3.97B

    MRK Cap

  • 0.01%

    DIV tootlus

LanZhou Foci Pharmaceutical Co.,Ltd. (002644-SZ) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 479.567 M, mis on 0.118 % gowth. Kogu perioodi keskmine brutokasum on 143.126 M, mis on 0.116 %. Keskmine brutokasumi suhtarv on 0.314 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -0.382 %, mis on võrdne 0.109 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes LanZhou Foci Pharmaceutical Co.,Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.023. Käibevara valdkonnas on 002644.SZ aruandlusvaluutas 1238.869. Märkimisväärne osa neist varadest, täpsemalt 406.041, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 0.019%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 79.875, kui neid on, aruandlusvaluutas. See näitab erinevust 19.813% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 1.346 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.812%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 1745.371 aruandlusvaluutas. Selle aspekti aastane muutus on 0.017%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 441.812, varude hind on 369.72 ja firmaväärtus 9.01, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 79.55.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

balance-sheet.row.cash-and-short-term-investments

1413.19406398.5374.9
452
434.7
465.5
70.2
418.6
499
275.6
161.8
190
325.5
67.8
18.7
9.3
6.6

balance-sheet.row.short-term-investments

-70.42-15.82-10.4
32.1
-18.2
-5.1
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

2046.86441.8526.5390.8
335.1
312
200.1
157
110.8
126.6
157.4
237.1
131.9
100.3
77.2
116.3
77.5
66.8

balance-sheet.row.inventory

1526.12369.7350.4258.8
258.3
286.8
241.3
196.6
191.2
159.3
138
124.7
150.2
140.1
85.6
79.9
76
48.1

balance-sheet.row.other-current-assets

74.0421.315.710
8.7
2.9
19.6
673.9
699.8
226.2
-2
-3
-4.4
-6.1
-3.8
-7.8
-1.3
-6.9

balance-sheet.row.total-current-assets

5060.221238.91291.11034.6
1054.1
1036.3
926.5
1097.7
1420.4
1011
569.1
520.8
467.7
559.7
226.8
207.1
161.5
114.6

balance-sheet.row.property-plant-equipment-net

4211.941061.81066.81091.6
1110.4
1134.5
1407.3
1100
471.2
220.6
319.8
294.1
267.8
183.2
151.7
137
136
138.5

balance-sheet.row.goodwill

26.9694.54.5
4.5
4.5
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

320.6679.676.872
74
75.8
124.8
127.6
118.7
120.3
147.9
84.5
85.4
84.7
71.9
74.2
101.3
104.2

balance-sheet.row.goodwill-and-intangible-assets

347.6388.681.376.4
78.5
80.3
124.8
127.6
118.7
120.3
147.9
84.5
85.4
84.7
71.9
74.2
101.3
104.2

balance-sheet.row.long-term-investments

335.9979.966.782.1
41.5
95.5
47.6
5.7
6.1
39.2
159.7
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

205.4153.652.451.1
51.3
53.6
5
5.4
4.9
4.2
2.9
2.5
2
1.6
1.5
0.7
0.5
1.5

balance-sheet.row.other-non-current-assets

54.245.328.416.2
51.3
0.4
12.9
13.5
15.4
-32.8
-152.8
1.2
0
0
4.3
3
1.3
1.3

balance-sheet.row.total-non-current-assets

5155.211289.21295.51317.5
1333
1364.3
1597.5
1252.2
616.3
351.4
477.5
382.3
355.2
269.5
229.4
214.9
239.1
245.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

10215.432528.12586.62352.1
2387.2
2400.7
2524
2349.8
2036.7
1362.4
1046.6
903.1
822.9
829.2
456.2
422
400.5
359.9

balance-sheet.row.account-payables

1338.65310.4311214.3
300.2
372.5
451.7
323.7
104.1
52.7
63.4
15.2
43.9
58.3
29.5
38.6
42.6
26.2

balance-sheet.row.short-term-debt

98.7424.713.814.7
34
14.5
17.3
0
0
0
26
124
76
76
46
46
59
34

balance-sheet.row.tax-payables

130.9535.169.447.6
49.2
48.5
7.7
13.3
2.6
2.5
2.4
3.6
4.1
12.2
10.3
3.5
1.4
2.4

balance-sheet.row.long-term-debt-total

14.551.30.50.8
66.6
80
387
109.4
108.1
0
0
0
2
2
2
2
2
15

Deferred Revenue Non Current

1056.95261278.2295
310.2
328.4
189.4
21.8
24.4
26.2
6.8
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

10.03---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

19.45.8110.94.5
1.1
13.4
30.3
47.2
32.1
34.8
11.2
6.1
4.3
3.7
3.8
11.6
1.7
4.8

balance-sheet.row.total-non-current-liabilities

1174.53292322.1349.8
377.6
409.3
576.4
619.8
610
41.2
197.4
38.9
14.7
13.6
13.4
11
10.6
25.2

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

3.231.30.50.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

3126.08759.7852.6724.6
800.1
893.8
1083.6
990.7
746.1
128.8
311.4
199.7
147.4
181.1
129.7
169.1
183.7
164.7

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

2042.63510.7510.7510.7
510.7
510.7
510.7
510.7
510.7
510.7
177.7
88.9
88.9
80.8
60.6
60.6
60.6
60.6

balance-sheet.row.retained-earnings

3119.21776.2746.9654.5
631.9
565.1
507.6
448.5
387.8
337.5
302.3
274.1
249.4
233.1
204.2
158.1
125.5
106.1

balance-sheet.row.accumulated-other-comprehensive-income-loss

1237.35158.4152143.6
133.8
123.9
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

605.87300.1305.8305.8
305.8
305.2
422.2
400
392.1
385.5
255.2
340.4
337.3
334.3
61.7
34.3
30.7
28.5

balance-sheet.row.total-stockholders-equity

7005.061745.41715.41614.6
1582.1
1504.9
1440.4
1359.1
1290.6
1233.7
735.2
703.4
675.5
648.1
326.5
253
216.8
195.2

balance-sheet.row.total-liabilities-and-stockholders-equity

10215.432528.12586.62352.1
2387.2
2400.7
2524
2349.8
2036.7
1362.4
1046.6
903.1
822.9
829.2
456.2
422
400.5
359.9

balance-sheet.row.minority-interest

84.2823.118.612.9
5
2
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

7089.351768.417341627.5
1587.1
1506.9
1440.4
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

10215.43---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

265.5764.168.771.7
73.6
77.3
42.5
5.7
6.1
39.2
159.7
0
0
0
0
0
0
0

balance-sheet.row.total-debt

113.292614.415.5
34
14.5
17.3
109.4
108.1
0
26
124
78
78
48
48
61
49

balance-sheet.row.net-debt

-1299.9-380-382.1-359.4
-386
-420.1
-448.3
39.2
-310.5
-499
-249.6
-37.8
-112
-247.5
-19.8
29.3
51.7
42.4

Rahavoogude aruanne

LanZhou Foci Pharmaceutical Co.,Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.401 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -34155286.360. See on -0.203 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 52.49, 1.77, -21.45, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -27.94 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui -1.26, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

cash-flows.row.net-income

58.1268.1105.993.5
111.7
74.7
74.3
74.1
60.9
42.9
34.7
30.6
30.4
32.1
51.2
36.1
21.6
23.3

cash-flows.row.depreciation-and-amortization

3.6352.549.548.6
38.7
53.1
34.2
21
18.5
17.9
14.9
15.2
14.1
6.3
11.3
12.5
13.7
0

cash-flows.row.deferred-income-tax

00.210.2
2.3
-40.7
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0-0.2-1-0.2
-2.3
40.7
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

66.85-82.3-112.2-117
-33
-86.9
-60.5
-32.5
-23.5
5
41.5
-65.2
-61.4
-45.7
11.3
-38
-39.7
0

cash-flows.row.account-receivables

59.559.5-210.1-66.8
-48.9
-84.7
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-7.3-7.3-91.7-0.8
28.9
-45.1
-45.1
-6.4
-31.9
-21.3
-13.3
25.5
-10.2
-54.5
-5.7
-3.9
-27.9
0

cash-flows.row.account-payables

0-134.7188.6-49.5
-17.8
83.5
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

14.640.210.2
4.8
-40.7
-15.3
-26.1
8.4
26.3
54.8
-90.7
-51.3
8.8
17
-34.1
-11.8
0

cash-flows.row.other-non-cash-items

-71.0327.429.1-13.2
-54.5
7
-11.3
3.8
1
-1.8
2.7
8.9
6
9.7
-17.7
-7.1
5
-23.3

cash-flows.row.net-cash-provided-by-operating-activities

57.56000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-8.98-22.5-41.5-32.8
-122.6
-93.2
-261.1
-442.8
-267
-51.9
-48.4
-85.8
-113.8
-69.9
-21.9
-23.3
-6.4
-107.6

cash-flows.row.acquisitions-net

-15.45-15.53.974.1
215.7
-9.7
261.3
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

8.95-6-2.1-3.9
-176.9
95.1
-45.4
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

7.988-3.938.1
144.5
42.9
14.2
0
0
0
0
0
0
0
0
0
0.5
2

cash-flows.row.other-investing-activites

-15.171.80.8-32.8
-122.6
-93.2
-261.1
0
496.3
4.5
172.8
0.1
0
0
15.9
46.6
0
0.2

cash-flows.row.net-cash-used-for-investing-activites

-22.66-34.2-42.842.6
-61.9
-58
-292.1
-442.8
229.3
-47.4
124.5
-85.7
-113.8
-69.9
-6
23.3
-5.9
-105.3

cash-flows.row.debt-repayment

-22.59-21.5-14.2-35.3
-14.5
-17.3
0
0
0
-63
-124
-80
-76
-46
-46
-59
-34
-34

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

-0.5000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-1.65-27.9-5.1-61.4
-31.9
-6.6
-6.6
-6.1
-4.6
-4.1
-6.4
-8.6
-7.8
-4.1
-2.5
-2.5
-4
-2.6

cash-flows.row.other-financing-activites

-11.1-1.33.93.3
22.9
3.3
13.3
2.3
91.9
495.2
26
156.4
73.1
375.4
47.5
44.3
46
32.7

cash-flows.row.net-cash-used-provided-by-financing-activities

-50.87-25-15.5-93.4
-23.5
-20.6
6.7
-3.8
87.3
428
-104.4
67.8
-10.7
325.3
-1
-17.3
8
-3.9

cash-flows.row.effect-of-forex-changes-on-cash

25.840.70.7-0.2
-0.1
-0.1
0
0
0
0.5
0
0.2
0.1
-0.1
-0.1
0
-0.1
-0.3

cash-flows.row.net-change-in-cash

9.867.214.8-39.1
-22.6
-30.9
-248.8
-380.2
373.6
445.3
113.8
-28.2
-135.5
257.7
49
9.5
2.7
-3.9

cash-flows.row.cash-at-end-of-period

1376.43396.3387.7372.9
412
434.7
465.5
714.3
1094.5
721
275.6
161.8
190
325.5
67.8
18.7
9.3
-3.9

cash-flows.row.cash-at-beginning-of-period

1366.56389.1372.9412
434.7
465.5
714.3
1094.5
721
275.6
161.8
190
325.5
67.8
18.7
9.3
6.6
0

cash-flows.row.operating-cash-flow

57.5665.772.411.9
62.9
47.8
36.7
66.4
56.9
64.1
93.7
-10.5
-11
2.4
56.2
3.5
0.6
105.6

cash-flows.row.capital-expenditure

-8.98-22.5-41.5-32.8
-122.6
-93.2
-261.1
-442.8
-267
-51.9
-48.4
-85.8
-113.8
-69.9
-21.9
-23.3
-6.4
-107.6

cash-flows.row.free-cash-flow

48.5843.230.9-21
-59.7
-45.3
-224.5
-376.3
-210.1
12.2
45.4
-96.3
-124.8
-67.5
34.3
-19.8
-5.8
-1.9

Kasumiaruande rida

LanZhou Foci Pharmaceutical Co.,Ltd. tulud muutusid võrreldes eelmise perioodiga 0.141%. 002644.SZ brutokasum on teatatud 361.3. Ettevõtte tegevuskulud on 261.96, mille muutus võrreldes eelmise aastaga on 102.488%. Kulud amortisatsioonikulud on 52.49, mis on -0.156% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 261.96, mis näitab 102.488% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.403% kasvu võrreldes eelmise aastaga. Tegevustulu on 83.27, mis näitab -0.403% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -0.382%. Eelmise aasta puhaskasum oli 67.19.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007

income-statement-row.row.total-revenue

1130.071163.11019.2817.6
668.1
628.8
544.6
501.1
363.3
327.6
399.1
291.5
266.4
271.2
262.4
232.2
219
177.5

income-statement-row.row.cost-of-revenue

765.41801.8733594.5
502.7
461.6
369.7
352.1
255
244.9
310.7
187.7
179.5
178
167.5
144.2
131.8
104.9

income-statement-row.row.gross-profit

364.66361.3286.2223.1
165.4
167.2
174.8
149.1
108.2
82.7
88.4
103.9
86.9
93.2
94.9
88
87.2
72.6

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

31.51---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

17.15---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

154.39---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-2.01-1.6-9.724.4
13.4
-26.1
0.3
2.2
6.3
7.6
10.9
9.5
6.9
4.8
24
13.5
1.3
-0.4

income-statement-row.row.operating-expenses

262.09262129.4134.6
109.4
98.3
112.8
89.3
74.1
65.3
67.5
71.6
55.5
55.8
57.5
56.1
56.7
38

income-statement-row.row.cost-and-expenses

1027.51063.8862.3729
612
560
482.6
441.4
329.1
310.2
378.2
259.2
235
233.8
225
200.3
188.5
142.9

income-statement-row.row.interest-income

2.935.47.510.2
12.8
16.3
12.4
30.9
31
23.5
10.2
2.5
2.3
0
0
0.1
0.1
0

income-statement-row.row.interest-expense

01.20.70.9
1.3
1.1
0.6
0
0
1
3.5
5.8
4.9
4.1
3.5
2.5
3.9
3

income-statement-row.row.selling-and-marketing-expenses

154.39---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-2.01-1.6-12.4-1.5
66.1
0.5
24.5
27.6
36.5
31.7
18.5
3.5
3.1
-1.1
18.3
8.7
-4.3
-7.3

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-2.01-1.6-9.724.4
13.4
-26.1
0.3
2.2
6.3
7.6
10.9
9.5
6.9
4.8
24
13.5
1.3
-0.4

income-statement-row.row.total-operating-expenses

-2.01-1.6-12.4-1.5
66.1
0.5
24.5
27.6
36.5
31.7
18.5
3.5
3.1
-1.1
18.3
8.7
-4.3
-7.3

income-statement-row.row.interest-expense

01.20.70.9
1.3
1.1
0.6
0
0
1
3.5
5.8
4.9
4.1
3.5
2.5
3.9
3

income-statement-row.row.depreciation-and-amortization

40.0652.562.232.2
38.7
63
34.2
21
18.5
17.9
14.9
15.2
14.1
6.3
11.3
12.5
13.7
9.7

income-statement-row.row.ebitda-caps

112.68---
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

72.6283.3139.4112.4
64.4
78.2
86.1
85.2
64.7
41.5
28.4
26.2
27.6
31.5
31.7
27.1
24.9
27.7

income-statement-row.row.income-before-tax

70.681.6127110.8
130.5
78.7
86.5
87.4
70.6
49.1
39.3
35.8
34.5
36.3
55.7
40.6
26.2
27.3

income-statement-row.row.income-tax-expense

11.2813.521.117.3
22.8
7.8
13.6
13.3
9.7
6.1
4.7
5.2
4.2
4.2
4.5
4.5
4.6
4

income-statement-row.row.net-income

58.1267.2108.793.3
108
71.1
72.9
74.1
60.9
42.9
34.7
30.6
30.4
32.1
51.2
36.1
21.6
23.3
Sarnased aktsiad
Sind võib huvitada ka:
CHSYF
China Medical System Holdings Limited.
0.9313 USD
PNK
TLLTF
TILT Holdings Inc..
0.0332 USD
PNK
600479.SS
ZhuZhou QianJin Pharmaceutical Co.,Ltd.
10.92 CNY
SHH
WOCKPHARMA.BO
Wockhardt Limited.
551.15 INR
BSE
185750.KS
Chong Kun Dang Pharmaceutical Corp..
100300 KRW
KSC
ERIS.NS
Eris Lifesciences Limited.
869.7 INR
NSE
300601.SZ
Shenzhen Kangtai Biological Products Co., Ltd..
22.39 CNY
SHZ
TKPHF
Takeda Pharmaceutical Company Limited.
26.616 USD
PNK
MVP.AX
Medical Developments International Limited.
0.61 AUD
ASX
APLLTD.NS
Alembic Pharmaceuticals Limited.
1024.3 INR
NSE
128940.KS
Hanmi Pharm. Co., Ltd..
321500 KRW
KSC

Korduma kippuv küsimus

Mis on LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) koguvara?

LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) koguvara on 2528102214.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 576952643.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.323.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on 0.095.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.051.

Mis on ettevõtte kogutulu?

Kogutulu on 0.064.

Mis on LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 67189706.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 26031519.000.

Mis on tegevuskulude arv?

Tegevuskulud on 261964435.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 365338610.000.